In mammals, estrogens have a multiplicity of effects ranging from control of differentiation of selected brain nuclei, reproductive functions, sexual behavior. In addition, these hormones influence the manifestation of disorders like depression and Alzheimer's. Study of the cells target for the hormone has shown that estrogen receptors (ERs) are expressed in all known neural cells, including microglia. In view of the potential interest in the use of estrogens in the therapy of several pathologies of the nervous system, it would be of interest to fully understand the mechanism of estrogen activity in the various neural target cells and get an insight on the molecular means allowing the hormone to display such a variety of effects. We have proposed the use of a reductionist approach for the systematic understanding of the estrogen activities in each specific type of target cell. Thus, we have generated a model system in which to study the activation of one of the known (ERs), estrogen receptor alpha. This system allowed us to identify a number of novel genes which expression may be influenced following the activation of this receptor subtype by estradiol (E 2 ). We here report on data recently obtained by the study of one of these target genes, nip2, which encodes a proapoptotic protein product. We hypothesize that nip2 might be an important molecular determinant for estrogen anti-apoptotic activity in cells of neural origin and represents a potential target for drugs aimed at mimicking the E 2 beneficial effects in neural cells.
Introduction
In the last decade, evidence has been accumulated that the role of estradiol (E 2 ) in the mammalian central nervous system (CNS) goes far beyond the control of reproductive functions. E 2 acts both in developing and in mature brain; during the differentiation of the nervous system it seems to regulate the differentiation of selected subsets of neurons [4] ; in the mature brain E 2 has a beneficial influence on memory mechanisms [28, 39] and on affective behavior [51] and it delays the onset of neurodegenerative disorders like Alzheimer's disease [19, 45, 10, 13, 26] . The understanding of the molecular mechanisms supporting E 2 positive effects would be of interest for the development of novel, specific drugs. However, the multiplicity of estrogen functions in neural cells reflects a complexity of action which limits the elucidation of its activities in molecular terms.
E 2 may modulate neural cell acti6ities through a 6ariety of mechanisms
The factors contributing to heterogeneous responses to E 2 in the nervous system are due to, (a) the multiplicity of estrogen receptors (ERs); (b) the nature of estrogen target cells; (c) the heterogeneity of signals which can activate intracellular ERs.
Multiplicity of ERs
It is well known that estrogens bind intracellular receptors members of a superfamily of hormonally-regulated transcription factors [47] . So far, two estrogen binding proteins have been described and named estrogen receptor a and b (ERa and ERb) [27, 25, 46, 15] . Both receptors reside in the target cell nucleus in a complex together with inhibitory proteins (heat shock proteins, such as Hsp90 and others).
The cognate hormone by binding the receptor determines the release of the inhibitory proteins; the estrogen-ER complex can at this point recognize specific DNA sequences (named estrogen responsive elements) in the promoter of target genes, whereby recruits the proteins of the transcription apparatus and triggers the synthesis of specific mRNAs. Alternatively, the ligandactivated receptors without binding to the DNA may directly interact with elements of the transcription machinery and modulate the activity of other transcription factors (e.g. NFkB, AP-I, SFRE [43, 49] . The genes coding for ERa and b share a high degree of structural homology [27] , particularly in the DNA binding (96%) and in the hormone binding (53%) domains. The N-terminus is the least homologous (30%); it is conceivable that this domain might establish distinct interactions with the proteins of the transcription apparatus and be responsible for a differential activity of the two receptors. So far, however, very little experimental evidence supports a different role of the two receptors once expressed in the same cell system. To verify whether the two receptors have a differential function, we studied a very well known effect of E 2 in neural cells, neurite sprouting. By transient transfection of SK-N-BE cells with one of the two receptors at a time we demonstrated that, in the same cell, E 2 (1 nM) induced a significantly different morphology in cells expressing ERa or b (Fig. 1) . This observation suggests that the two receptors have a distinct effect on the same target cell. We actually proved that this is indeed the case by cotransfecting with ERa or b dominant negative mutants of the small G protein Rac1b, known to play an important role in microtubule assembly. This experiment demonstrated that the signaling pathway of ERa, but not ERb, involves this small G protein further substantiating our hypothesis (Fig. 2) [36] . In addition to the above mentioned intracellular receptors, several authors have recently proposed the existence of membrane receptors for estrogens [32] Smith et al., 1989, [50, 33, 18, 38] , the evidence for this hypothesis being electrophysiological studies which indicate a functional link between membrane E 2 -binding proteins and calcium channels. There are also a number of studies showing E 2 -dependent activation of other transduction signaling molecules (cAMP, [17] , Ca 2 + [22, 21] , inositol-3-phosphate kinase, diacylglicerol, src [5] , CREB, ERK-1, ERK-2 [44] further suggesting the possibility that E 2 binds to acceptor sites located in the cytoplasmic membrane.
These putative membrane receptors, however, are still unknown from the biochemical point of view. [36] . As we showed also with stable transfections, the estrogen-dependent activation of SK-N-BE cells expressing ERa results in a morphological change which can be quantitated by assessing the extent of neurite elongation and the number of neurites generated at a fixed day (e.g. sixth day following the treatment with the hormone). The morphological change induced by estradiol was significantly different in cells transfected with ERb. In this case, SK-N-BE morphological differentiation lead to the generation of uni-or bi-polar cells with morphology clearly distinguishable from cells transfected with the ER subtype. Upper panels: SK-N-BE cells transiently transfected with plasmids coding for bGAL alone (left), ER and bGAL (middle), ERb and bGAL (right). Lower panels: The cells transfected as above were treated for 6 days with 1 nM E 2 . ERa-expressing cells (middle) acquire a star-shaped morphology with an average of four to five neurites per cell, while ERb-transfected cells (right) show a bipolar structure with a maximum of two neurites per cell. 
All neural cell types may be target for estrogen acti6ity
Intracellular ERs can be found in all the neural cells, neurons and glial cells like oligodendrocytes and astrocytes [23, 40] . In addition, recent, unpublished results from our laboratory, show that ERs are present also in rat microglial cells (Vegeto et al., unpublished data). Interestingly, localization studies indicate that ERa and b are generally expressed in different areas of the CNS [41, 42, 3] . It is conceivable, therefore, that in each specific target cell the estrogen triggers differential responses by activating selected target genes.
Acti6ation of ER in the absence of the cognate ligand
Studies originally carried out in O'Malley's laboratory [37] and then by several other authors [20, 6, 30, 24, 34, 35] have shown that ERa can be transcriptionally activated by neurotransmitters and growth factors also in the absence of the cognate ligand. In particular, dopamine [37] , insulin, IGF-1 [30] and EGF [20] may control ERa transcriptional activity, possibly by phosphorylation of the receptor itself or of the coactivators/repressors interacting with it [6, 24, 35] . This interaction between intracellular and membrane receptors has been referred to as cross-talk (Fig. 3) .
In view of the number of cells and genes targeted by this multifunctional receptor, the finding of differential mechanisms controlling its transcriptional activation leads to hypothesize that the above-mentioned crosstalk has evolved in order to limit the large ER potential by appropriate, differential hormone stimuli. We have proposed that this mechanism may be of relevance especially during the differentiation of the CNS [34] by allowing IGF-I to activate the ER. This would explain why, at least in rat, ERs are synthesized in several brain areas very early during the differentiation of the CNS while the high levels of circulating alpha-fetoproteins restrain estrogen access to the target cells [48] .
SK-ER3 neuroblastoma cells, a tool for the understanding of the molecular e6ents induced by estrogens in neural cells
The obvious consequence to what is said above is that the understanding of the molecular events triggered by the hormone-receptor complex in the whole brain tissue is not informative because any effect on target gene activities could represent the summation of a series of responses to the hormone in the various target cells. On this line of thought, a few years ago we proposed to generate a neuroblastoma cell line in which the activities of a single receptor (ERa) [29] could be systematically studied in a specific cell system. To this goal, we stably transfected hERa cDNA in the human neuroblastoma cell line (SK-N-BE). We then characterized the cell line generated (Fig. 4) and (i) proved that it contains a number of receptors similar to other estrogen target cells (about 200 fmoles/mg cytosolic protein), (ii) that the hormone and DNA binding activity of the transfected receptors are indistinguishable from those previously reported in other cell lines and (iii) that the receptor is transcriptionally active [29] . Interestingly, our studies showed that in the SK-ER3 cell line the E 2 -dependent activation of ERa results in growth arrest and differentiation towards the dopamin-ergic phenotype [1, 2] . In view of the close links between the dopaminergic system and estrogen responsive cells in the CNS we proposed that the cell line we generated might recapitulate at least some of the events occurring during the differentiation of the CNS and continued our studies with the identification of genes regulated by estrogens in cells of neural origin. The technique applied was differential display PCR. We were able to isolate 11 DNA fragments representing genes modulated by E 2 , in SK-ER3 model system [14] .
The question thus arising, regarded the physiological relevance of the genes identified in E 2 action in neural cells.
Nip2, a protein product whose expression correlates with cell death
One of the genes whose expression was negatively modulated by E 2 , nip2, had been described earlier by Boyd [11] as coding for a Bcl-2 binding protein. We, therefore, initiated a series of experiments aimed at clarifying the role of nip2 in cell activities.
O6erexpression of nip2 correlates with cell death.
We initially observed the consequences of nip2 overexpression in neuroblastoma cells. A series of transient transfections proved that nip2 overexpression resulted in rapid cell death. The effect was dose-dependent [31] and could be blocked by Bcl-2 coexpression [9] . Further proof of the correlation between cell death and overexpression of nip2 was obtained by measuring the content of nip2 mRNA in cells exposed to toxic stimuli. All the neurotoxic agents, glucose deprivation, calcium ionophore, b-amyloid peptide, determined a rapid increase in nip2 expression which was then followed by the onset of pre-apoptotic events, like change in membrane polarity, and by cell death.
1.2.1.2. E 2 down regulates nip2 expression and blocks neuroblastoma cell apoptosis. In SK-ER3 cells, treatment with 10 nM E 2 results in a significant decrease of nip2 mRNA levels. Time course studies show that this effect is maximal at 4 h and then decreases with time. At 24 h after the treatments, nip2 mRNA levels are back to control values [31] . Interestingly, in the same study, in a time course experiment taking into consideration the efficacy of E 2 anti-apoptotic activity we showed that E 2 may counteract the effect of neurotoxic agents only if it is administered before the toxic compounds and the protective effect of E 2 is maximal when given 16 h before the toxic insult. These observations led us to hypothesize that the down-modulation of nip2 expression might be instrumental in the anti-apoptotic activity of E 2 in neuroblastoma cells. 
Discussion
In the latest years, several authors have shown that E 2 exerts anti-apoptotic activity in neural cells exposed to a variety of toxic insults [7, 19, 8, 16] . The mechanisms involved in this activity is still controversial since several authors favor a non genomic-, while others a genomic-mediated effect of the hormone. Our studies indicate that E 2 may modulate the synthesis of factors relevant in the apoptotic cascade of events and therefore point to the importance of E 2 -dependent genomic effects in neural cell protection against toxic stimuli. While the effects of E 2 on nip2 activity await to be further studied in in vivo models, it is important to underlay that the neuroprotective effects of estrogens may be the result of a series of activities exerted on the different cell types present in the CNS. For instance, estrogens may enhance the synthesis and secretion of growth factors from glial cells as well as exert antiinflammatory activities in microglia [12] . These activities would contribute to enhance the survival of neurons and to limit the accumulation of toxic substances, respectively. We are therefore focusing on the effect of the hormone also in cells other than neurons.
Our studies provide some background for the understanding of the molecular signaling underlying E 2 protective effects, which might be of interest also for cells other than neural (e.g. mammary gland). The finding of specific target for estrogen action may lead to the design of novel drugs aimed at reproducing the beneficial effects of the hormone, in the absence of the undesired ones.
